Elromo 50mg Tablet

Elromo 50mg Tablet is prescribed by the doctor to treat low platelet counts in specific blood-related conditions. It is mainly given in combination with other medicines to treat a particular condition or increase effectiveness. Elromo 50mg Tablet contains Eltrombopag Olamine that promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet formation and reduced bleeding risk in conditions like chronic ITP, hepatitis C-related thrombocytopenia, or severe aplastic anemia.

Elromo 50mg Tablet can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.
● Headache
● Nausea
● Tiredness
● Diarrhea
● Insomnia
● Dizziness
● Loss of Appetite
● Rashes
● Muscle Pain
● Fever
● Chills
● Allergic Reaction
● Liver Problem
● Blood Clots
● Allergic Reaction

The usual dose of Elromo 50mg Tablet is one tablet daily. It should be taken on an empty stomach, at the same time each day for consistent blood levels. Consult your doctor for individual dosage as it may vary person to person based on its stage and overall health.Tablet is taken orally with the help of water. Avoid breaking, chewing, biting and crushing of tablet to maintain the medication efficacy.

Elromo 50mg Tablet contains Eltrombopag Olamine, Eltrombopag binds to and activates the transmembrane domain of the TPO receptor (c-Mpl) on megakaryocyte progenitors in the bone marrow, triggering signaling pathways. This promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet formation and reduced bleeding risk in conditions like chronic ITP, hepatitis C-related thrombocytopenia, or severe aplastic anemia.

• Garnock-Jones, K. P., & Keam, S. J. (2009). Eltrombopag. Drugs, 69(5), 567-576.
• Gonzalez-Porras, J. R., & Bastida, J. M. (2018). Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Therapeutic advances in drug safety, 9(6), 263-285.
• Lozano, M. L., Segú-Vergés, C., Coma, M., Álvarez-Roman, M. T., González-Porras, J. R., Gutiérrez, L., ... & Butta, N. (2021). Elucidating the mechanism of action of the attributed immunomodulatory role of eltrombopag in primary immune thrombocytopenia: an in silico approach. International journal of molecular sciences, 22(13), 6907.
• Raslova, H., Vainchenker, W., & Plo, I. (2016). Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica, 101(12), 1443.